Roche extends tender offer for Spark Therapeutics

The period for Roche’s offer of $114.50 per share for U.S.-based Spark has been extended several times and was set to expire on Dec. 10.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.